Up­dat­ed: Al­ny­lam de­lays high­ly-an­tic­i­pat­ed AT­TR read­out as it changes study de­sign

Al­ny­lam is mak­ing a se­ries of changes to a close­ly-watched study of its AT­TR amy­loi­do­sis drug vutrisir­an that will de­lay the Phase III read­out from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.